The brief
Peptide news, written like a log. What changed. What isn’t approved. Dated. Cited.
Latest
News
Retatrutide is not approved anywhere
Eli Lilly filed six U.S. lawsuits over black-market retatrutide. The drug is in Phase 3. No regulator has approved it.
News
Illicit GLP-1 seizures more than doubled in July
CBP told Reuters the July figures more than doubled from the fiscal-year tally. Enforcement, not a shop list.
News
216 suspected death reports is not 216 proven deaths
UK press circulated MHRA Yellow Card totals. Suspected is not proven. No new label change.
News
The UK authorised a GLP-1 tablet
On 10 August 2026 the MHRA authorised orforglipron (Foundayo). First in Europe. Prescription-only. Not on the NHS yet.
News
Retatrutide is not filed. Lilly says Q1 2027.
Lilly said the clinical package is complete and it plans a BLA in Q1 2027. Not approved. Not filed.
News
An FDA panel voted on six peptides. That is not approval.
On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee recommended six peptides for the 503A Bulks List. The vote is advisory.
Always
Evergreen
A notes app is not a log
Two mornings collapse into one memory in a notes app. A log keeps the name, the time, and which bottle.
Evergreen
What people mean by BPC-157 and TB-500
Two names that get said together. Neither is an FDA-approved drug. A July 2026 advisory vote is not approval.
Evergreen
Three kinds of peptides
Approved medicines, compounded copies, and research-only listings are not the same thing. Mixing the words is how people get lost.